Merck and Moderna release detailed cancer vaccine data at ESMO
The companies presented detailed results for an individualized mRNA vaccine combined with pembrolizumab in high-risk melanoma.
TL;DR
- Merck and Moderna presented detailed Phase 3 results for their personalized mRNA cancer vaccine at the ESMO meeting.
- The companies reported a 42% reduction in recurrence-or-death risk when the vaccine was combined with pembrolizumab versus pembrolizumab alone.
- The findings concern high-risk melanoma and do not establish regulatory approval or effectiveness across other cancers.
Merck and Moderna presented additional results from a Phase 3 study of an individualized mRNA vaccine, intismeran autogene, combined with pembrolizumab for high-risk melanoma. STAT reported the presentation at the European Society for Medical Oncology meeting, and Reuters separately covered the results. [1] [2]
The companies reported that the combination reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. Reuters described the trial as involving 1,137 patients; the result was presented as a relative risk reduction. [1] [2]
The comparison was between the vaccine-plus-pembrolizumab regimen and pembrolizumab alone in the studied melanoma population. It does not by itself quantify an individual patient’s absolute benefit or show that the same result applies to other tumor types. [1] [2]
The reports describe clinical results, not a completed regulatory review. Further questions include the full benefit-risk profile, durability of the effect, and whether the approach can be extended to additional cancers. [1] [2]
Why it matters
The results add clinical evidence to a personalized cancer-vaccine program while keeping the evidence tied to one disease setting and a defined combination regimen. The next milestones are regulatory assessment and evidence about the approach’s durability and breadth.
Editor's note
Headlined from STAT’s report. Numbers and population reflect the cited reporting; the 42% figure is a relative risk reduction. No regulatory approval is implied.